Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1986 Feb;77(2):496–502. doi: 10.1172/JCI112329

Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.

D J Fitzgerald, J Doran, E Jackson, G A FitzGerald
PMCID: PMC423371  PMID: 3003161

Abstract

The use of enzyme inhibitors to clarify the role of thromboxane A2 in vasoocclusive disease has been complicated by their non-specific action. To address this problem we have examined the effects of thromboxane A2/prostaglandin endoperoxide receptor antagonism in a canine model of platelet-dependent coronary occlusion. Two structurally distinct thromboxane A2/prostaglandin endoperoxide receptor antagonists, 3-carboxyl-dibenzo (b, f) thiepin-5,5-dioxide (L636,499) and (IS-(1 alpha,2 beta(5Z),3 beta,4 alpha))-7-(3-((2-((phenylamino)-carbonyl)hydrazino)methyl)-7- oxabicy-clo(2.2.1)-hept-2-yl)-5-heptenoic acid (SQ 29,548), were studied to ensure that the effects seen in vivo were mediated by receptor antagonism and did not reflect a nonspecific drug effect. Both compounds specifically inhibited platelet aggregation induced by arachidonic acid and by the prostaglandin endoperoxide analogue, U46619, in vitro and ex vivo, and increased the time to thrombotic vascular occlusion in vivo. When an antagonist (L636,499) was administered at the time of occlusion in vehicle-treated dogs, coronary blood flow was restored. In vitro L636,499 and a third antagonist, 13-azaprostanoic acid, specifically reversed endoperoxide-induced platelet aggregation and vascular smooth muscle contraction. Neither compound altered cyclic AMP in platelet-rich plasma before or during disaggregation. Therefore, reversal of coronary occlusion may reflect disaggregation of platelets and/or relaxation of vascular smooth muscle at the site of thrombus formation through specific antagonism of the thromboxane A2/prostaglandin endoperoxide receptor. Thromboxane A2/prostaglandin endoperoxide receptor antagonists are compounds with therapeutic potential which represent a novel approach to defining the importance of thromboxane A2 and/or endoperoxide formation in vivo.

Full text

PDF
496

Images in this article

498Image
on p.498

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aiken J. W., Shebuski R. J., Miller O. V., Gorman R. R. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. J Pharmacol Exp Ther. 1981 Nov;219(2):299–308. [PubMed] [Google Scholar]
  2. Armstrong R. A., Jones R. L., Wilson N. H. Ligand binding to thromboxane receptors on human platelets: correlation with biological activity. Br J Pharmacol. 1983 Aug;79(4):953–964. doi: 10.1111/j.1476-5381.1983.tb10541.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. BORN G. V., CROSS M. J. THE AGGREGATION OF BLOOD PLATELETS. J Physiol. 1963 Aug;168:178–195. doi: 10.1113/jphysiol.1963.sp007185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bertelé V., Falanga A., Tomasiak M., Cerletti C., de Gaetano G. SQ 22536, an adenylate-cyclase inhibitor, prevents the antiplatelet effect of dazoxiben, a thromboxane-synthetase inhibitor. Thromb Haemost. 1984 Feb 28;51(1):125–128. [PubMed] [Google Scholar]
  5. Cardinal D. C., Flower R. J. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J Pharmacol Methods. 1980 Feb;3(2):135–158. doi: 10.1016/0160-5402(80)90024-8. [DOI] [PubMed] [Google Scholar]
  6. Carrier R., Cragoe E. J., Ethier D., Ford-Hutchinson A. W., Girard Y., Hall R. A., Hamel P., Rokach J., Share N. N., Stone C. A. Studies on L-640,035: a novel antagonist of contractile prostanoids in the lung. Br J Pharmacol. 1984 Jun;82(2):389–395. doi: 10.1111/j.1476-5381.1984.tb10774.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chan C. C., Nathaniel D. J., Yusko P. J., Hall R. A., Ford-Hutchinson A. W. Inhibition of prostanoid-mediated platelet aggregation in vivo and in vitro by 3-hydroxymethyl-dibenzo(b,f)thiepin 5,5-dioxide (L-640,035). J Pharmacol Exp Ther. 1984 Apr;229(1):276–282. [PubMed] [Google Scholar]
  8. Chignard M., Vargaftig B. Dog platelets fail to aggregate when they form aggregating substances upon stimulation with arachidonic acid. Eur J Pharmacol. 1976 Jul;38(1):7–18. doi: 10.1016/0014-2999(76)90195-3. [DOI] [PubMed] [Google Scholar]
  9. FitzGerald G. A., Brash A. R., Oates J. A., Pedersen A. K. Endogenous prostacyclin biosynthesis and platelet function during selective inhibition of thromboxane synthase in man. J Clin Invest. 1983 Oct;72(4):1336–1343. doi: 10.1172/JCI111089. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. FitzGerald G. A., Sherry S. Pharmacology and pharmacokinetics of platelet-active drugs under current clinical investigation. Adv Prostaglandin Thromboxane Leukot Res. 1982;10:107–172. [PubMed] [Google Scholar]
  11. Fitzpatrick F. A., Bundy G. L., Gorman R. R., Honohan T. 9,11-epoxyiminoprosta-5,13-dienoic acid is a thromboxane A2 antagonist in human platelets. Nature. 1978 Oct 26;275(5682):764–766. doi: 10.1038/275764a0. [DOI] [PubMed] [Google Scholar]
  12. Fitzpatrick F. A., Gorman R. R., Mc Guire J. C., Kelly R. C., Wynalda M. A., Sun F. F. A radioimmunoassay for thromboxane B2. Anal Biochem. 1977 Sep;82(1):1–7. doi: 10.1016/0003-2697(77)90127-0. [DOI] [PubMed] [Google Scholar]
  13. Folts J. D., Gallagher K., Rowe G. G. Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation? Circulation. 1982 Feb;65(2):248–255. doi: 10.1161/01.cir.65.2.248. [DOI] [PubMed] [Google Scholar]
  14. Granström E., Diczfalusy U., Hamberg M., Hansson G., Malmsten C., Samuelsson B. Thromboxane a2: biosynthesis and effects on platelets. Adv Prostaglandin Thromboxane Leukot Res. 1982;10:15–58. [PubMed] [Google Scholar]
  15. Grimm L. J., Knapp D. R., Senator D., Halushka P. V. Inhibition of platelet thromboxane synthesis by 7-(1-imidazolyl) heptanoic acid: dissociation from inhibition of aggregation. Thromb Res. 1981 Nov 15;24(4):307–317. doi: 10.1016/0049-3848(81)90004-9. [DOI] [PubMed] [Google Scholar]
  16. Haerem J. W. Sudden coronary death: the occurrence of platelet aggregates in the epicardial arteries of man. Atherosclerosis. 1971 Nov-Dec;14(3):417–432. doi: 10.1016/0021-9150(71)90070-0. [DOI] [PubMed] [Google Scholar]
  17. Harper J. F., Brooker G. Femtomole sensitive radioimmunoassay for cyclic AMP and cyclic GMP after 2'0 acetylation by acetic anhydride in aqueous solution. J Cyclic Nucleotide Res. 1975;1(4):207–218. [PubMed] [Google Scholar]
  18. Heptinstall S., Bevan J., Cockbill S. R., Hanley S. P., Parry M. J. Effects of a selective inhibitor of thromboxane synthetase on human blood platelet behaviour. Thromb Res. 1980 Oct 15;20(2):219–230. doi: 10.1016/0049-3848(80)90387-4. [DOI] [PubMed] [Google Scholar]
  19. Horn P. T., Kohli J. D., LeBreton G. C., Venton D. L. Antagonism of prostanoid-induced vascular contraction by 13-azaprostanoic acid (13-APA). J Cardiovasc Pharmacol. 1984 Jul-Aug;6(4):609–613. doi: 10.1097/00005344-198407000-00009. [DOI] [PubMed] [Google Scholar]
  20. Hung S. C., Ghali N. I., Venton D. L., Le Breton G. C. Specific binding of the thromboxane A2 antagonist 13-azaprostanoic acid to human platelet membranes. Biochim Biophys Acta. 1983 Feb;728(2):171–178. doi: 10.1016/0005-2736(83)90468-6. [DOI] [PubMed] [Google Scholar]
  21. Ignarro L. J., Lippton H., Edwards J. C., Baricos W. H., Hyman A. L., Kadowitz P. J., Gruetter C. A. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther. 1981 Sep;218(3):739–749. [PubMed] [Google Scholar]
  22. Le Breton G. C., Venton D. L. Thromboxane A2 receptor antagonism selectively reverses platelet aggregation. Adv Prostaglandin Thromboxane Res. 1980;6:497–503. [PubMed] [Google Scholar]
  23. Lewis H. D., Jr, Davis J. W., Archibald D. G., Steinke W. E., Smitherman T. C., Doherty J. E., 3rd, Schnaper H. W., LeWinter M. M., Linares E., Pouget J. M. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med. 1983 Aug 18;309(7):396–403. doi: 10.1056/NEJM198308183090703. [DOI] [PubMed] [Google Scholar]
  24. Lindgren J. A., Claesson H. E., Kindahl H., Hammarström S. Effects of platelet aggregation and adenosine 3':5'-monophosphate on the synthesis of thromboxane B2 in human platelets. Adv Prostaglandin Thromboxane Res. 1980;6:275–281. [PubMed] [Google Scholar]
  25. Mais D. E., Kochel P. J., Saussy D. L., Jr, Halushka P. V. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets. Mol Pharmacol. 1985 Aug;28(2):163–169. [PubMed] [Google Scholar]
  26. Myers A., Penhos J., Ramey E., Ramwell P. Thromboxane agonism and antagonism in a mouse sudden death model. J Pharmacol Exp Ther. 1983 Feb;224(2):369–372. [PubMed] [Google Scholar]
  27. Nishikawa M., Kanamori M., Hidaka H. Inhibition of platelet aggregation and stimulation of guanylate cyclase by an antianginal agent molsidomine and its metabolites. J Pharmacol Exp Ther. 1982 Jan;220(1):183–190. [PubMed] [Google Scholar]
  28. Ogletree M. L., Harris D. N., Greenberg R., Haslanger M. F., Nakane M. Pharmacological actions of SQ 29,548, a novel selective thromboxane antagonist. J Pharmacol Exp Ther. 1985 Aug;234(2):435–441. [PubMed] [Google Scholar]
  29. Parise L. V., Venton D. L., Le Breton G. C. Arachidonic acid-induced platelet aggregation is mediated by a thromboxane A2/prostaglandin H2 receptor interaction. J Pharmacol Exp Ther. 1984 Jan;228(1):240–244. [PubMed] [Google Scholar]
  30. Patscheke H., Stegmeier K. Investigation on a selective non-prostanoic thromboxane antagonist, BM 13.177, in human platelets. Thromb Res. 1984 Feb 1;33(3):277–288. doi: 10.1016/0049-3848(84)90163-4. [DOI] [PubMed] [Google Scholar]
  31. Romson J. L., Bush L. R., Haack D. W., Lucchesi B. R. The beneficial effects of oral ibuprofen on coronary artery thrombosis and myocardial ischemia in the conscious dog. J Pharmacol Exp Ther. 1980 Oct;215(1):271–278. [PubMed] [Google Scholar]
  32. Romson J. L., Haack D. W., Lucchesi B. R. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of anti-thrombotic agents. Thromb Res. 1980 Mar 15;17(6):841–853. doi: 10.1016/0049-3848(80)90249-2. [DOI] [PubMed] [Google Scholar]
  33. Steiner A. L., Kipnis D. M., Utiger R., Parker C. Radioimmunoassay for the measurement of adenosine 3',5'-cyclic phosphate. Proc Natl Acad Sci U S A. 1969 Sep;64(1):367–373. doi: 10.1073/pnas.64.1.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Venton D. L., Enke S. E., Le Breton G. C. Azaprostanoic acid derivatives. Inhibitors of arachidonic acid induced platelet aggregation. J Med Chem. 1979 Jul;22(7):824–830. doi: 10.1021/jm00193a014. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES